Literature DB >> 3381230

Placental and milk transfer of chloroquine in humans.

A Akintonwa1, S A Gbajumo, A F Mabadeje.   

Abstract

The placental and milk transfer of chloroquine was studied in seven subjects and six subjects, respectively. Seven pregnant women at term were administered chloroquine phosphate (5 mg/kg) i.m. The maternal blood and arterial and venous umbilical cord blood were obtained during delivery. The maternal chloroquine blood levels varied from 0.438 to 1.193 micrograms/ml. The venous cord blood ranged from 0.607 to 0.869, whereas the arterial levels ranged from 0.480 to 0.905 micrograms/ml. Six subjects who were administered chloroquine phosphate (5 mg/kg) postpartum had chloroquine milk levels of 0.192-0.319 micrograms/ml. The milk:blood ratio ranged from 0.268 to 0.462. Chloroquine readily crossed the placenta and was excreted into the breast milk.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3381230     DOI: 10.1097/00007691-198802000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  11 in total

Review 1.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

2.  Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers.

Authors:  Irwin Law; Kenneth F Ilett; L Peter Hackett; Madhu Page-Sharp; Francesca Baiwog; Servina Gomorrai; Ivo Mueller; Harin A Karunajeewa; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

3.  Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.

Authors:  Els Keyaerts; Sandra Li; Leen Vijgen; Evelien Rysman; Jannick Verbeeck; Marc Van Ranst; Piet Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics in the treatment of rheumatoid arthritis in pregnancy.

Authors:  F R Witter
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

Review 5.  Optimisation of antirheumatic drug treatment in pregnancy.

Authors:  M Ostesen
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

6.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

7.  Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Authors:  Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade
Journal:  J Cutan Med Surg       Date:  2018-11-21       Impact factor: 2.092

Review 8.  Malaria in Pregnancy: What the Obstetric Provider in Nonendemic Areas Needs to Know.

Authors:  Arthurine K Zakama; Stephanie L Gaw
Journal:  Obstet Gynecol Surv       Date:  2019-09       Impact factor: 2.347

Review 9.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

10.  Transplacental transfer of genotoxins and transplacental carcinogenesis.

Authors:  H Autrup
Journal:  Environ Health Perspect       Date:  1993-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.